Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Trading Halts

Proteon Therapeutics (PRTO) PT Lowered to $1 at BairdMarch 28, 2019 11:19 AM Maxim Group Downgrades Proteon Therapeutics (PRTO) to HoldMarch 28, 2019 10:42 AM Proteon Therapeutics (PRTO) to Resume Trading at 8:30 am ETMarch 28, 2019 8:08 AM Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous FistulasMarch 28, 2019 8:00 AM